TWS119
Based on 34 publication(s) in Google Scholar
TWS119 is an inhibitor of GSK-3β, with an IC50 of 30 nM, and activates the wnt/β-catenin pathway.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.89%
- CAS No.: 601514-19-6
- Formule: C18H14N4O2
- Masse moléculaire:318.33
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Kinase Inhibitor Library
HY-L009
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
Glucose Metabolism Compound Library
HY-L092
-
Antidepressant Compound Library
HY-L108
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
Kinase Inhibitor Library Mini
HY-L009M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Protein Kinase Compound Library
HY-L196
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) TWS119
More- Nat Commun. 2025 Apr 30;16(1):4060. [Abstract]
- Sci Adv. 2023 Sep 29;9(39):eadg8148. [Abstract]
- Research (Wash D C). 2025 Dec 10:8:1030. [Abstract]
- Cell Death Dis. 2025 Nov 3;16(1):786. [Abstract]
- Environ Sci Technol. 2023 Feb 14;57(6):2351-2361. [Abstract]
- Cancer Lett. 2021 Jan 1:496:57-71. [Abstract]
- Cell Commun Signal. 2024 Aug 7;22(1):391. [Abstract]
- NPJ Biofilms Microbiomes. 2024 Jan 20;10(1):5. [Abstract]
- Mol Ther Oncol. 2025 Apr 24;33(2):200986. [Abstract]
- Cell Rep. 2024 May 10;43(5):114226. [Abstract]
- Cancer Cell Int. 2021 Jun 5;21(1):291. [Abstract]
- J Agric Food Chem. 2026 Jul 8;74(26):20662-20673. [Abstract]
- Biochem Pharmacol. 2023 Dec:218:115903. [Abstract]
- Life Sci. 2019 Oct 15:235:116844. [Abstract]
- Am J Physiol Cell Physiol. 2019 Dec 1;317(6):C1115-C1127. [Abstract]
- J Lipid Res. 2019 Dec;60(12):2020-2033. [Abstract]
- Prog Neurobiol. 2024 Sep:240:102654. [Abstract]
- FASEB J. 2023 Mar;37(3):e22821. [Abstract]
- Aquacul Rep. 2021, 100774.
- Pathol Res Pract. 2023 Sep:249:154719. [Abstract]
- J Dent Sci. 2024 Jan;19(1):428-437. [Abstract]
- Front Mar Sci. 2021 Jul.
- SLAS Discov. 2024 Nov 5;29(8):100191. [Abstract]
- Neuroscience. 2018 Jul 15:383:129-137. [Abstract]
- Curr Eye Res. 2021 Feb;46(2):159-167. [Abstract]
- bioRxiv. 2026 May 22.
- Sci Total Environ. 2026 Jan 15:1012:181191. [Abstract]
- Patent. US20240325538A1.
- Patent. US20240238271A1.
- Research Square Preprint. 2024 Jan 31.
- Patent. US20230226111A1.
- Oxid Med Cell Longev. 2021 Mar 19:2021:5595376. [Abstract]
- Research Square Preprint. 2020 Dec.
- Patent. US20180263995A1.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
Activité biologique
|
GSK-3β 30 nM (IC50) |
TWS119 induces neuronal differentiation in P19 EC cells and primary mouse ESCs. TWS119 (< 4 μM) significantly enhances the proliferation and survival of γδT cells via activation of the mammalian target of rapamycin (mTOR) pathway, upregulation of the expression of anti-apoptotic protein Bcl-2 and inhibition of cleaved caspase-3. TWS119 (0-8 μM) induces the generation of CD62L+γδT or CCR5+γδT cell phenotypes. TWS119 (0.5, 1.0 and 2 μM) increases the expression level of granzyme B in a dose-dependent manner. TWS119 also enhances the cytolytic activity of γδT cells against tumour cells in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 601514-19-6
-
Appearance Solid
-
Masse moléculaire 318.33
-
Formule C18H14N4O2
-
Color Off-white to yellow
-
SMILES
OC1=CC=CC(OC2=C3C(NC(C4=CC=CC(N)=C4)=C3)=NC=N2)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (34)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression. [Abstract]2025 Apr 30;16(1):4060. PMID: 40307251 -
Sci Adv
CHI3L1 signaling impairs hippocampal neurogenesis and cognitive function in autoimmune-mediated neuroinflammation. [Abstract]2023 Sep 29;9(39):eadg8148. PMID: 37756391 -
Research (Wash D C)
Single-Cell Profiling Identifies Reward Behavior-Related Neurons and Alterations in the Ventral Tegmental Area Based on Arvcf-Knockout Mouse Model. [Abstract]2025 Dec 10:8:1030. PMID: 41395251 -
Cell Death Dis
Atypical cadherin CELSR2 acts as a therapeutic target for glioma through WNT3A/β-catenin signaling. [Abstract]2025 Nov 3;16(1):786. PMID: 41184253 -
Environ Sci Technol
Phosphorus Overload Promotes Hepatic Lipolysis by Suppressing GSK3β-Dependent Phosphorylation of PPARα at Ser84 and Thr265 in a Freshwater Teleost. [Abstract]2023 Feb 14;57(6):2351-2361. PMID: 36728683 -
Cancer Lett
2021 Jan 1:496:57-71. PMID: 33038488 -
Cell Commun Signal
Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis. [Abstract]2024 Aug 7;22(1):391. PMID: 39113090 -
NPJ Biofilms Microbiomes
Endogenous Coriobacteriaceae enriched by a high-fat diet promotes colorectal tumorigenesis through the CPT1A-ERK axis. [Abstract]2024 Jan 20;10(1):5. PMID: 38245554
TWS119 purchased from MedChemExpress. Usage Cited in: NPJ Biofilms Microbiomes. 2024 Jan 20;10(1):5. [Abstract]
Percentage cell proliferation of CT26 cells treated with MEK inhibitor U0126-EtOH (HY-12031; 25 µM), JNK inhibitor SP600125 (HY-12041; 25 µM), P38/MAPK inhibitor SB202190 (HY-10295; 20 µM), GSK3β inhibitor TWS119 (HY-10590; 20 µM), or AR-A014418 (HY-10512; 20 µM), and vehicle or Cori.ST1911. Cell OD was measured using the CCK8 method and normalised to cell proliferation of the control. Inhibitor treatment started 4 h before Cori.ST1911 treatment. Data are represented as mean ± SEM (n = 3 independent tests), analysed by one-way analysis of variance (ANOVA) with Bonferroni’s post-hoc test. n.s., no significance.
-
Mol Ther Oncol
Epstein-Barr virus mRNA vaccine synergizes with NK cells to enhance nasopharyngeal carcinoma eradication in humanized mice. [Abstract]2025 Apr 24;33(2):200986. PMID: 40458686 -
Cell Rep
Astrocyte-derived CHI3L1 signaling impairs neurogenesis and cognition in the demyelinated hippocampus. [Abstract]2024 May 10;43(5):114226. PMID: 38733586 -
Cancer Cell Int
Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. [Abstract]2021 Jun 5;21(1):291. PMID: 34090418 -
J Agric Food Chem
Enantioselective Neurotoxicity of Pydiflumetofen in Zebrafish Embryos: R-Enantiomer Disrupts Neurodevelopment via Suppression of Wnt/β-Catenin Signaling. [Abstract]2026 Jul 8;74(26):20662-20673. PMID: 42345402 -
Biochem Pharmacol
Serinc2 deficiency exacerbates sepsis-induced cardiomyopathy by enhancing necroptosis and apoptosis. [Abstract]2023 Dec:218:115903. PMID: 37918695 -
Life Sci
XQ-1H alleviates cerebral ischemia in mice through inhibition of apoptosis and promotion of neurogenesis in a Wnt/β-catenin signaling dependent way. [Abstract]2019 Oct 15:235:116844. PMID: 31499069 -
Am J Physiol Cell Physiol
cGMP-dependent protein kinase II determines β-catenin accumulation that is essential for uterine decidualization in mice. [Abstract]2019 Dec 1;317(6):C1115-C1127. PMID: 31509448 -
J Lipid Res
CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-cateninT120/TCF21 pathway. [Abstract]2019 Dec;60(12):2020-2033. PMID: 31662443 -
Prog Neurobiol
Astrocyte-secreted C3 signaling impairs neuronal development and cognition in autoimmune diseases. [Abstract]2024 Sep:240:102654. PMID: 38945516 -
FASEB J
GSK-3β/β-catenin pathway plays crucial roles in the regulation of NK cell cytotoxicity against myeloma cells. [Abstract]2023 Mar;37(3):e22821. PMID: 36794671
TWS119 purchased from MedChemExpress. Usage Cited in: FASEB J. 2023 Mar;37(3):e22821. [Abstract]
TWS119 substantially increases NF-κB phosphorylation in NK-92 cells.
-
-
Pathol Res Pract
2023 Sep:249:154719. PMID: 37595446 -
J Dent Sci
MiR-34a functions as a tumor suppressor in oral cancer through the inhibition of the Axl/Akt/GSK-3β pathway. [Abstract]2024 Jan;19(1):428-437. PMID: 38303867 -
-
SLAS Discov
Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ. [Abstract]2024 Nov 5;29(8):100191. PMID: 39510350 -
Neuroscience
Lithium Posttreatment Alleviates Blood-Brain Barrier Injury After Intracerebral Hemorrhage in Rats. [Abstract]2018 Jul 15:383:129-137. PMID: 29775701 -
Curr Eye Res
Human Amniotic Epithelial Cells Promote the Proliferation of Human Corneal Endothelial Cells by Regulating Telomerase Activity via the Wnt/β-catenin Pathway. [Abstract]2021 Feb;46(2):159-167. PMID: 32631162 -
-
Sci Total Environ
Activation of the Wnt/β-catenin pathway attenuates the acute toxic effects of copper exposure in Penaeus vannamei. [Abstract]2026 Jan 15:1012:181191. PMID: 41418521 -
-
-
-
-
Oxid Med Cell Longev
A Green and Blue Monochromatic Light Combination Therapy Reduces Oxidative Stress and Enhances B-Lymphocyte Proliferation through Promoting Melatonin Secretion. [Abstract]2021 Mar 19:2021:5595376. PMID: 33828639 -
-
Solvant et solubilité
DMSO : ≥ 50 mg/mL (157.07 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
PBMCs are cultured with pamidronate disodium for 8 days and then cells are labelled with or without 1.5 μM carboxyfluorescein succinimidyl ester (CFSE) and CFSE-labelled cells are then seeded in 6-well plates (2.5 × 106 cells/well) followed by treatment with various concentrations of TWS119 for 72 h. The total number of cultured cells is evaluated using an automated cell counter and the γδT cell proliferation is examined by flow cytometry[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
All rats are randomly divided into four groups as follows: Sham group-rats undego the same surgical procedure, but the filament is not inserted and they receive 1 mL of dimethyl sulfoxide (1 % DMSO in saline); Vehicle group-rats undergo MCAO and receive 1 mL of DMSO; rtPA group-rats underwent MCAO and receive rtPA (10 mg/kg, Actilyse®) at 4 h after MCAO; and rtPA+TWS119 group-rats undergo MCAO and receive intraperitoneal TWS119 (30 mg/kg, dissolved in 1 mL 1 % DMSO) immediately after rtPA injection at 4 h after MCAO[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Wang W, et al. GSK-3β inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/β-catenin signaling pathway after acute ischemic stroke in rats. Mol Neurobiol. 2016 Dec;53(10):7028-7036. Epub 2015 Dec 15. [Content Brief]
[2]. Chen YQ, et al. Wnt pathway activator TWS119 enhances the proliferation and cytolytic activity of human γδT cells against colon cancer. Exp Cell Res. 2017 Nov 16. pii: S0014-4827(17)30587-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1414 mL | 15.7070 mL | 31.4139 mL | 78.5349 mL |
| 5 mM | 0.6283 mL | 3.1414 mL | 6.2828 mL | 15.7070 mL | |
| 10 mM | 0.3141 mL | 1.5707 mL | 3.1414 mL | 7.8535 mL | |
| 15 mM | 0.2094 mL | 1.0471 mL | 2.0943 mL | 5.2357 mL | |
| 20 mM | 0.1571 mL | 0.7853 mL | 1.5707 mL | 3.9267 mL | |
| 25 mM | 0.1257 mL | 0.6283 mL | 1.2566 mL | 3.1414 mL | |
| 30 mM | 0.1047 mL | 0.5236 mL | 1.0471 mL | 2.6178 mL | |
| 40 mM | 0.0785 mL | 0.3927 mL | 0.7853 mL | 1.9634 mL | |
| 50 mM | 0.0628 mL | 0.3141 mL | 0.6283 mL | 1.5707 mL | |
| 60 mM | 0.0524 mL | 0.2618 mL | 0.5236 mL | 1.3089 mL | |
| 80 mM | 0.0393 mL | 0.1963 mL | 0.3927 mL | 0.9817 mL | |
| 100 mM | 0.0314 mL | 0.1571 mL | 0.3141 mL | 0.7853 mL |
TWS119 Related Classifications
HY-10590 Related Classifications
Powered by Bioz